Stoke Therapeutics (STOK) Revenue (2022 - 2026)

Stoke Therapeutics' Revenue history runs 5 years deep, the most recent figure standing at $6.2 million for Q1 2026.

• In Q1 2026, Revenue fell 96.07% year-over-year to $6.2 million; the TTM figure through Mar 2026 stood at $32.1 million (down 83.2% YoY), while the FY2025 annual figure was $184.4 million, up 404.5% from the prior year.
• Revenue was $6.2 million for Q1 2026 at Stoke Therapeutics, up from $1.4 million in the prior quarter.
• In the past five years, Revenue ranged from a high of $158.6 million in Q1 2025 to a low of $1.4 million in Q4 2025.
• Historically, Revenue has averaged $14.9 million across 5 years, with a median of $4.2 million in 2024.
• The sharpest annual moves came in 2025 and 2026: Revenue jumped 3661.12% in 2025, then slumped 96.07% in 2026.
• A 5-year view of Revenue shows it stood at $3.3 million in 2022, then retreated by 14.26% to $2.8 million in 2023, then soared by 707.07% to $22.6 million in 2024, then sank by 93.8% to $1.4 million in 2025, then soared by 344.29% to $6.2 million in 2026.
• The last three Revenue figures came in at $6.2 million (Q1 2026), $1.4 million (Q4 2025), and $10.6 million (Q3 2025), per Business Quant data.